Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
- Asahi Kasei Pharma Licenses Chronic Pain Drug AK1780 to Eli Lilly
February 1, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Fujifilm Toyama Chemical Files Radiopharmaceutical F-1614
January 29, 2021
- Pfizer Japan Files Somatrogon for Growth Hormone Deficiency
January 29, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
- Ono Seeks Pediatric Nod for Opdivo in Hodgkin’s Lymphoma
January 29, 2021
- Life Science Institute to Test Muse Cell Therapy in ALS
January 29, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
- Forxiga Gets Priority Review Status for CKD in Japan: AZ
January 29, 2021
- SymBio, Univ. of Tokyo Jointly Explore New Indications for Bendamustine, Rigosertib
January 29, 2021
- Sawai Gains Japan Rights for Israeli Firm’s Digital Device for Migraines; Eyes Filing in 2022
January 29, 2021
- Nichi-Iko Puts Mesalazine Supply on Hold over Variations in API Content in Latest Lots
January 29, 2021
- Supply Control for Beova to Last until FY2022: Kyorin/Kissei
January 29, 2021
- Pfizer, Viatris Control Shipment of 9 APIs over Kobayashi Kako, Nichi-Iko Recall Havoc
January 29, 2021
- Bristol Myers Donates 5.5 Billion Yen to Kyoto University to Support I/O Research
January 28, 2021
- Kobayashi Kako Issues Yet Another Recall, Now for 12 APIs/21 Products
January 28, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…